Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Clinical Studies

1 - 1 of 1

Humanized CART19 phase 2 trial

This is a phase 2 study to determine the efficacy of huCART19 in pediatric and young adult patients with CD19-expressing high-risk relapsed or refractory B-cell acute lymphoblastic leukemia. The targeted population is patients 1-29 years with CD19-expressing high-risk relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), including patients who previously received a B cell-directed cell therapy.